Skip to main content
Diabetes Therapy logoLink to Diabetes Therapy
. 2020 May 2;11(7):1607–1608. doi: 10.1007/s13300-020-00820-2

Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring—Study Design

Tadej Battelino 1,, Zsolt Bosnyak 2, Thomas Danne 3, Bhaswati Mukherjee 2, Steve Edelman 4, Valerie Pilorget 2, Pratik Choudhary 5,6, Eric Renard 7,8,9, Richard Bergenstal 10
PMCID: PMC7324444  PMID: 32361833

Correction to: Diabetes Ther (2020) 11:1017–1027 10.1007/s13300-020-00781-6

In the original publication, the timing of baseline CGM assessment was incorrectly stated in the text in two instances; it is correct in Fig. 1.

In the “Data Collection” section, the sentence “Baseline and investigational CGM values are assessed during weeks 0–3 and 9–12, respectively…” should state “Baseline and investigational CGM values are assessed during weeks −3 to 0 and 9 to 12, respectively…”

In the “Statistical Analysis” section, the sentence “The percentage of time in the glucose range of ≥ 70 to ≤ 180 mg/dL (≥ 3.9 to ≤ 10 mmol/L) at week 12 will be assessed in both arms using 20 days of blinded CGM data during weeks 0–3 and 9–12” should state “The percent time in the glucose range of ≥ 70 to ≤ 180 mg/dL (≥ 3.9 to ≤ 10 mmol/L) at week 12 will be assessed using data generated during the randomised period.”

Open Access

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.


Articles from Diabetes Therapy are provided here courtesy of Springer

RESOURCES